Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Off-Pump Bypass Surgery Reduces Certain Risks

By HospiMedica staff writers
Posted on 06 Dec 2006
Off-pump coronary artery bypass graft (CABG) surgery reduces the risk of complications such as stroke and atrial fibrillation, according to a new study.

Researchers from the U.S. More...
Agency for Healthcare Research and Quality (AHRQ, Rockville, MD, USA) analyzed data from 41 clinical trials that included 3,996 patients who underwent CABG after 1999. The researchers compared the off-pump approach to the traditional cardiopulmonary bypass (CPB) procedure, which stops the heart to allow surgeons to create the new pathways. The researchers found that the off-pump procedure resulted in a 50% reduction in the risk faced by patients undergoing the surgery; a 30% reduction in the risk of atrial fibrillation; and a 48% reduction in wound infection.

The study also found that off-pump surgery often involves fewer grafts to bypass coronary lesions as compared with traditional surgery. In addition, the study showed evidence that off-pump surgeries are more successfully performed at facilities that perform many of them. These findings appeared in the November 2006 issue of the journal Stroke.

"Off-pump CABG carries its own risks, and requires substantial training to learn and perform comfortably,” said lead author Artyom Sedrakyan, M.D., Ph.D., a cardiothoracic surgeon and health services researcher at AHRQ. "We look forward to more research on long-term outcomes and in settings outside trials to learn more about this important surgery.”

CABG, pioneered in 1967, creates new paths around blocked arteries to improve blood flow to the heart. The risks of adverse effects on heart, brain, lungs, kidney, and other organs, have led some surgeons to consider off-pump CABG as a less-invasive alternative.



Related Links:
U.S. Agency for Healthcare Research and Quality

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.